HOME >> BIOLOGY >> NEWS
Marker predicts pancreatic cancer outcome after surgery, Jefferson surgeon finds

A team of researchers, led by surgeons at the Kimmel Cancer Center at Jefferson in Philadelphia, has found further evidence supporting the ability of a protein to predict how well a patient with advanced pancreatic cancer will do after surgery, chemotherapy and radiation. The levels of the protein CA 19-9 in the blood can be used to determine the need for further therapy, they say.

Adam Berger, M.D., assistant professor of surgery at Jefferson Medical College of Thomas Jefferson University, and his co-workers examined CA 19-9 levels and the survival of 385 patients with advanced pancreatic cancer who were treated with surgery and subsequent chemotherapy and radiation. They found that those patients whose post-operative CA 19-9 level exceeded 180 U/ml did much worse than those with lower levels.

In fact, at least half of those whose CA 19-9 level was higher than 180 U/ml lived for approximately nine months, while half of those whose levels were 180 or below lived more than twice as long, about 21 months. After three years, about 30 percent of those with levels 180 or under were still alive, while virtually none of the patients with levels above 180 remained alive. He reports his teams findings June 23, 2007 at the semi-annual meeting of the Radiation Therapy Oncology Group (RTOG) in Philadelphia.

We think that it is a very sensitive predictor of response to chemotherapy and radiation after surgery, says Dr. Berger.

The main goal of the multicenter trial was to compare pancreatic cancer surgery patients who received two different types of chemotherapy 5FU or gemcitabine along with radiation. It was designed to look at CA 19-9 levels and survival after surgery as a secondary goal. Patients submitted blood samples prior to chemotherapy, which were analyzed for CA 19-9. Overall, 385 patients had levels that could be analyzed.

According to Dr. Berger, a post-surgery CA 19-9 level of 180 or less translated to a 72
'"/>

Contact: Steven Benowitz
Steven.Benowitz@jefferson.edu
215-955-6300
Thomas Jefferson University
22-Jun-2007


Page: 1 2

Related biology news :

1. Markers of gene, protein, or micro-RNA activity predict outcome in prostate and colorectal cancers
2. Markers found for bacterial vaginosis
3. Markers of brain cell development may help success of stem cell transplants
4. Gene predicts better outcome as cortex normalizes in teens with ADHD
5. Major study predicts grim future for Europes seas
6. FDG-PET imaging clearly predicts lung cancer patients response to chemotherapy
7. NASA predicts nongreen plants on other planets
8. Gene profiling predicts resistance to breast cancer drug Herceptin
9. Mathematical model predicts cholera outbreaks
10. New test predicts blood cancers sensitivity to experimental cancer drug
11. Blood test predicts cardiac events and death in heart patients

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/9/2019)... ... July 09, 2019 , ... Murrieta Genomics, a ... incubator program. The founder and CEO of Tx Genetic, Helen Harrison, has spent ... suffering from epithelial connective tissue disorders. , “We are pleased and excited to ...
(Date:6/25/2019)... ... June 25, 2019 , ... ActX ... raw data, easily available from 23andMe, customers can get access to professionally reviewed ... available for both 23andMe Ancestry and Health + Ancestry customers., With the ActX ...
(Date:6/16/2019)... ... June 14, 2019 , ... Respected periodontist, Dr. ... fifth annual Neodent World Congress. Attended by thousands of dental clinicians from all ... in the world of dentistry. The three-day event featured a team of expert ...
Breaking Biology News(10 mins):
(Date:5/31/2019)... City, California (PRWEB) , ... ... ... allowance of our patent applications from the USPTO providing proprietary interest to ... AND METHOD FOR SLEEP DISORDER DIAGNOSIS AND TREATMENT… extends Somnology’s IP rights ...
(Date:5/22/2019)... ... May 22, 2019 , ... Artemis (formerly Agrilyst), the leading ... A funding round co-led by Astanor Ventures and Talis Capital ... and iSelect Fund . The company has raised $11.75m to date and will ...
(Date:5/14/2019)... TOWNSHIP, N.J. (PRWEB) , ... May 13, 2019 ... ... of custom built, helium-based leak testing instruments for the Pharmaceutical, Biotechnology, Medical Device ... new Heliumleak.com company website. The redesigned website aims to improve LDA’s ability to ...
(Date:5/4/2019)... SÃO PAULO, Brazil (PRWEB) , ... May 03, ... ... the lecture given by the President of the Dakila Pesquisas Association, the scientist ... of the Councilmen 2019, in Brasília (DF). Urandir detailed the results of some ...
Breaking Biology Technology:
Cached News: